deltatrials
Recruiting PHASE2 INTERVENTIONAL 1-arm NCT03617133

Image Guided IMRT, Radiochemotherapy and MRI-based IGABT in Locally Advanced Cervical Cancer (EMBRACEII)

Image Guided Intensity Modulated External Beam Radiochemotherapy and MRI Based Adaptive BRAchytherapy in Locally Advanced CErvical Cancer

Sponsor: Aarhus University Hospital

Conditions Uterine Cervical Neoplasms
Interventions Adaptation of EBRT nodal elective CTV according to risk of nodal and systemic recurrence EBRT dose prescription and reporting EBRT target concept related to the primary tumor (CTV-T) and internal motion; concepts for OAR contouring Increased use of IC/IS technique in BT Reduction of overall treatment time Reduction of vaginal source loading Systematic utilisation of IMRT Systemic application of simultaneous chemotherapy Utilisation of daily IGRT (set-up according to bony structures)
Updated 12 times since 2018 Last updated: Mar 1, 2022 Started: Apr 30, 2016 Primary completion: Dec 31, 2021 Completion: Apr 30, 2031
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Uterine Cervical Neoplasms and is currently actively recruiting participants. Aarhus University Hospital leads this study, which shows 12 recorded versions since 2016 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Sep 2018 – ~Feb 2020 · 17 months · monthly snapshotRecruiting~Feb 2020 – ~Mar 2020 · 29 days · monthly snapshotRecruiting~Mar 2020 – ~Jun 2020 · 3 months · monthly snapshotRecruiting~Jun 2020 – ~Jan 2021 · 7 months · monthly snapshotRecruiting~Jan 2021 – ~May 2021 · 4 months · monthly snapshotRecruiting~May 2021 – ~Oct 2021 · 5 months · monthly snapshotRecruiting~Oct 2021 – ~Apr 2022 · 6 months · monthly snapshotRecruiting~Apr 2022 – ~Oct 2022 · 6 months · monthly snapshotRecruiting~Oct 2022 – ~Apr 2024 · 18 months · monthly snapshotRecruiting~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshotRecruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotRecruiting~Sep 2024 – present · 22 months · monthly snapshotRecruiting

Change History

12 versions recorded

  1. Sep 2024 — Present [monthly]

    Recruiting PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

  3. Apr 2024 — Jul 2024 [monthly]

    Recruiting PHASE2

  4. Oct 2022 — Apr 2024 [monthly]

    Recruiting PHASE2

  5. Apr 2022 — Oct 2022 [monthly]

    Recruiting PHASE2

▶ Show 7 earlier versions

  1. Oct 2021 — Apr 2022 [monthly]

    Recruiting PHASE2

  2. May 2021 — Oct 2021 [monthly]

    Recruiting PHASE2

  3. Jan 2021 — May 2021 [monthly]

    Recruiting PHASE2

  4. Jun 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  5. Mar 2020 — Jun 2020 [monthly]

    Recruiting PHASE2

  6. Feb 2020 — Mar 2020 [monthly]

    Recruiting PHASE2

  7. Sep 2018 — Feb 2020 [monthly]

    Recruiting PHASE2

    First recorded

Apr 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Aarhus University Hospital
  • Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
  • Cambridge University Hospitals NHS Foundation Trust
  • Catharina Ziekenhuis Eindhoven
  • Chulalongkorn University
  • Complejo Hospitalario de Navarra
  • Cross Cancer Institute
  • Erasmus Medical Center
  • Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
  • Gustave Roussy, Cancer Campus, Grand Paris
  • Hospital Clinic of Barcelona
  • Institut Bergonié
  • Institut Català d'Oncologia
  • Institute of Oncology Ljubljana
  • Leiden University Medical Center
  • Liverpool Hospital, Sydney
  • Loyola University Chicago
  • Ludwig-Maximilians - University of Munich
  • M.D. Anderson Cancer Center
  • Maastro Clinic, The Netherlands
  • Maisonneuve-Rosemont Hospital
  • McGill University
  • Medical University of Vienna
  • Mount Vernon Cancer Centre
  • National Cancer Institute, Slovakia
  • North Estonia Medical Centre
  • Odense University Hospital
  • Oslo University Hospital
  • Pamela Youde Nethersole Eastern Hospital
  • Post Graduate Institute of Medical Education and Research, Chandigarh
  • Princess Margaret Hospital, Canada
  • Radboud University Medical Center
  • Radiotherapiegroep
  • Region Örebro County
  • Rigshospitalet, Denmark
  • Royal Marsden NHS Foundation Trust
  • Siriraj Hospital
  • Skane University Hospital
  • St Thomas' Hospital, London
  • Tata Memorial Centre
  • The Christie NHS Foundation Trust
  • The Leeds Teaching Hospitals NHS Trust
  • The Netherlands Cancer Institute
  • Tom Baker Cancer Centre
  • Tuen Mun Hospital
  • UMC Utrecht
  • Universitaire Ziekenhuizen KU Leuven
  • University Hospital Heidelberg
  • University Hospitals Bristol and Weston NHS Foundation Trust
  • University Hospitals Coventry and Warwickshire NHS Trust
  • University of Pittsburgh
Data source: Medical University of Vienna

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations